Latest NCCN 2017 of lung cancer also bring forword PD-L1 expression of ≥50% is a cutoff value for guiding the application of PD1/PDL1 antibodies therapy in NSCLC patients in 1st line. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.